{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:29:04Z","timestamp":1786408144539,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K08900"],"award-info":[{"award-number":["JP22K08900"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Intrahepatic cholangiocellular carcinoma (ICC) has poor prognosis, especially with lymph node (LN) metastasis (LNM). Lysine methyltransferase SET and MYND domain-containing 2 (SMYD2) has critical roles and is reportedly associated with poor prognosis in various cancers, but the role of SMYD2 in ICC is unclear. Here, we examined the role of SMYD2 in the progression of LNM of ICC. We immunohistochemically analyzed SMYD2 expression using resected specimens first in primary ICC and then in metastatic LNs derived from ICC. For functional analyses, we then performed cell proliferation assay following SMYD2 inhibition using two ICC cell lines such as HuCCT-1 and HuH28. To explore the detailed mechanisms of LNM, immunocytochemistry and western blotting related to epithelial-mesenchymal transition (EMT) were first performed. Moreover, we performed clinically immunohistochemical staining of C-C motif chemokine receptor 7 (CCR7) in metastatic LNs, immunofluorescence staining and western blotting for functional analyses to evaluate the relationship between SMYD2 and CCR7. Finally, p65 of nuclear factor-kappa B (NF-\u03baB) and phospho-p65 (Ser536) status were checked as the regulator of CCR7. Protein expression levels of SMYD2 in the primary ICC lesion were not associated with any clinicopathological characteristics or prognosis. However, SMYD2 was expressed in metastatic LNs of all cases and LNM was strongly associated with poor disease-free and overall survival also as previously reported. This study therefore aimed to clarify the molecular-biological roles for LNM by SMYD2. SMYD2 knockdown significantly inhibited ICC cell proliferation. According to subsequent EMT-related research, SMYD2 knockdown did not induce morphological changes or cadherin switching. Next, chemotaxis assay revealed that SMYD2 knockdown reduced chemotaxis in HuCCT-1 from metastatic ascites but not in HuH28 from the primary lesion. CCR7 expression in metastatic LNs was immunologically confirmed in all cases and had a positive correlation with SMYD2 expression. Decreased expression of CCR7 was observed in SMYD2-suppressed HuCCT-1 cells by immunofluorescence staining and western blotting simultaneously with the decreasing phosphorylation of p65\n                    <jats:sup>S536<\/jats:sup>\n                    . SMYD2 could be demonstrated to express in all metastatic LNs derived from ICC and may regulate this metastatic mechanism through CCR7-dependent chemotaxis rather than EMT via the SMYD2-phospho-p65\n                    <jats:sup>S536<\/jats:sup>\n                    -CCR7 pathway.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-55155-y","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T02:23:35Z","timestamp":1780280615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SMYD2 regulates lymph node metastasis derived from intrahepatic cholangiocellular carcinoma through CCR7-dependent chemotaxis"],"prefix":"10.1038","volume":"16","author":[{"given":"Masashi","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4177-6281","authenticated-orcid":false,"given":"Shinya","family":"Hayami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Suzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Shigekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kitahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Motobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Ehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Hamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"55155_CR1","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/hepr.13953","volume":"53","author":"H Iijima","year":"2023","unstructured":"Iijima, H. et al. Report of the 23rd nationwide follow-up survey of primary liver cancer in Japan (2014\u20132015). Hepatol. Res. 53, 895\u2013959. https:\/\/doi.org\/10.1111\/hepr.13953 (2023).","journal-title":"Hepatol. Res."},{"key":"55155_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","volume":"248","author":"I Endo","year":"2008","unstructured":"Endo, I. et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann. Surg. 248, 84\u201396. https:\/\/doi.org\/10.1097\/SLA.0b013e318176c4d3 (2008).","journal-title":"Ann. Surg."},{"key":"55155_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00534-010-0349-2","volume":"18","author":"K Uchiyama","year":"2011","unstructured":"Uchiyama, K. et al. Impact of nodal involvement on surgical outcomes of intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J. Hepatobiliary Pancreat. Sci. 18, 443\u2013452. https:\/\/doi.org\/10.1007\/s00534-010-0349-2 (2011).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"55155_CR4","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/jco.2011.35.6519","volume":"29","author":"MC de Jong","year":"2011","unstructured":"de Jong, M. C. et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J. Clin. Oncol. 29, 3140\u20133145. https:\/\/doi.org\/10.1200\/jco.2011.35.6519 (2011).","journal-title":"J. Clin. Oncol."},{"key":"55155_CR5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/archsurg.2012.1962","volume":"147","author":"D Ribero","year":"2012","unstructured":"Ribero, D. et al. Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: A multi-institutional analysis of 434 patients. Arch. Surg. 147, 1107\u20131113. https:\/\/doi.org\/10.1001\/archsurg.2012.1962 (2012).","journal-title":"Arch. Surg."},{"key":"55155_CR6","doi-asserted-by":"publisher","first-page":"e1187","DOI":"10.1097\/SLA.0000000000003788","volume":"274","author":"XF Zhang","year":"2021","unstructured":"Zhang, X. F. et al. Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis. Ann. Surg. 274, e1187\u2013e1195. https:\/\/doi.org\/10.1097\/SLA.0000000000003788 (2021).","journal-title":"Ann. Surg."},{"key":"55155_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/jhbp.1038","volume":"29","author":"Y Umeda","year":"2022","unstructured":"Umeda, Y. et al. Impact of lymph node dissection on clinical outcomes of intrahepatic cholangiocarcinoma: Inverse probability of treatment weighting with survival analysis. J. Hepatobiliary Pancreat. Sci. 29, 217\u2013229. https:\/\/doi.org\/10.1002\/jhbp.1038 (2022).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"55155_CR8","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721 (2010).","journal-title":"N. Engl. J. Med."},{"key":"55155_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka, T. et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J. Hepatobiliary Pancreat. Sci. 30, 102\u2013110. https:\/\/doi.org\/10.1002\/jhbp.1219 (2023).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"55155_CR10","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh, D. Y. et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 1, EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015 (2022).","journal-title":"NEJM Evid."},{"key":"55155_CR11","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/s0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1853\u20131865. https:\/\/doi.org\/10.1016\/s0140-6736(23)00727-4 (2023).","journal-title":"Lancet"},{"key":"55155_CR12","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1593\/neo.12656","volume":"14","author":"HS Cho","year":"2012","unstructured":"Cho, H. S. et al. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia 14, 476\u2013486. https:\/\/doi.org\/10.1593\/neo.12656 (2012).","journal-title":"Neoplasia"},{"key":"55155_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-59","volume":"9","author":"S Hayami","year":"2010","unstructured":"Hayami, S. et al. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F\/RB pathway. Mol. Cancer 9, 59. https:\/\/doi.org\/10.1186\/1476-4598-9-59 (2010).","journal-title":"Mol. Cancer"},{"key":"55155_CR14","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/ijc.25366","volume":"128","author":"M Yoshimatsu","year":"2011","unstructured":"Yoshimatsu, M. et al. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int. J. Cancer 128, 562\u2013573. https:\/\/doi.org\/10.1002\/ijc.25366 (2011).","journal-title":"Int. J. Cancer"},{"key":"55155_CR15","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ijc.25349","volume":"128","author":"S Hayami","year":"2011","unstructured":"Hayami, S. et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 128, 574\u2013586. https:\/\/doi.org\/10.1002\/ijc.25349 (2011).","journal-title":"Int. J. Cancer"},{"key":"55155_CR16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/0008-5472.CAN-10-2446","volume":"71","author":"HS Cho","year":"2011","unstructured":"Cho, H. S. et al. Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res. 71, 655\u2013660. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2446 (2011).","journal-title":"Cancer Res."},{"key":"55155_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1593\/neo.11512","volume":"13","author":"HS Cho","year":"2011","unstructured":"Cho, H. S. et al. Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. Neoplasia 13, 676\u2013684. https:\/\/doi.org\/10.1593\/neo.11512 (2011).","journal-title":"Neoplasia"},{"key":"55155_CR18","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1593\/neo.11048","volume":"13","author":"G Toyokawa","year":"2011","unstructured":"Toyokawa, G. et al. Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia 13, 887\u2013898. https:\/\/doi.org\/10.1593\/neo.11048 (2011).","journal-title":"Neoplasia"},{"key":"55155_CR19","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1158\/1940-6207.CAPR-11-0290","volume":"4","author":"G Toyokawa","year":"2011","unstructured":"Toyokawa, G. et al. The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6. Cancer Prev Res (Phila) 4, 2051\u20132061. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-11-0290 (2011).","journal-title":"Cancer Prev Res (Phila)"},{"key":"55155_CR20","doi-asserted-by":"publisher","first-page":"E179","DOI":"10.1002\/ijc.26501","volume":"131","author":"HS Cho","year":"2012","unstructured":"Cho, H. S. et al. The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1\/S transition in cancer cells via transcriptional regulation of the HOXA1 gene. Int. J. Cancer 131, E179-189. https:\/\/doi.org\/10.1002\/ijc.26501 (2012).","journal-title":"Int. J. Cancer"},{"key":"55155_CR21","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1158\/0008-5472.CAN-11-3701","volume":"72","author":"M Takawa","year":"2012","unstructured":"Takawa, M. et al. Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression. Cancer Res. 72, 3217\u20133227. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3701 (2012).","journal-title":"Cancer Res."},{"key":"55155_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/gcc.22012","volume":"52","author":"D Kang","year":"2013","unstructured":"Kang, D. et al. The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis. Genes Chromosomes Cancer 52, 126\u2013139. https:\/\/doi.org\/10.1002\/gcc.22012 (2013).","journal-title":"Genes Chromosomes Cancer"},{"key":"55155_CR23","doi-asserted-by":"publisher","first-page":"34320","DOI":"10.18632\/oncotarget.26144","volume":"9","author":"Y Shigekawa","year":"2018","unstructured":"Shigekawa, Y. et al. Overexpression of KDM5B\/JARID1B is associated with poor prognosis in hepatocellular carcinoma. Oncotarget 9, 34320\u201334335. https:\/\/doi.org\/10.18632\/oncotarget.26144 (2018).","journal-title":"Oncotarget"},{"key":"55155_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/cas.16038","volume":"115","author":"H Kato","year":"2024","unstructured":"Kato, H. et al. Histone methyltransferase SUV420H1\/KMT5B contributes to poor prognosis in hepatocellular carcinoma. Cancer Sci. 115, 385\u2013400. https:\/\/doi.org\/10.1111\/cas.16038 (2024).","journal-title":"Cancer Sci."},{"key":"55155_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nature05287","volume":"444","author":"J Huang","year":"2006","unstructured":"Huang, J. et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 444, 629\u2013632. https:\/\/doi.org\/10.1038\/nature05287 (2006).","journal-title":"Nature"},{"key":"55155_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neo.2014.03.002","volume":"16","author":"L Piao","year":"2014","unstructured":"Piao, L. et al. The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells. Neoplasia 16, 257\u2013264. https:\/\/doi.org\/10.1016\/j.neo.2014.03.002 (2014).","journal-title":"Neoplasia"},{"key":"55155_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.canlet.2014.05.014","volume":"351","author":"R Hamamoto","year":"2014","unstructured":"Hamamoto, R., Toyokawa, G., Nakakido, M., Ueda, K. & Nakamura, Y. SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation. Cancer Lett. 351, 126\u2013133. https:\/\/doi.org\/10.1016\/j.canlet.2014.05.014 (2014).","journal-title":"Cancer Lett."},{"key":"55155_CR28","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/carcin\/bgp116","volume":"30","author":"S Komatsu","year":"2009","unstructured":"Komatsu, S. et al. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 30, 1139\u20131146. https:\/\/doi.org\/10.1093\/carcin\/bgp116 (2009).","journal-title":"Carcinogenesis"},{"key":"55155_CR29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/bjc.2014.543","volume":"112","author":"S Komatsu","year":"2015","unstructured":"Komatsu, S. et al. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer. Br. J. Cancer 112, 357\u2013364. https:\/\/doi.org\/10.1038\/bjc.2014.543 (2015).","journal-title":"Br. J. Cancer"},{"key":"55155_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0347-x","volume":"9","author":"LX Li","year":"2018","unstructured":"Li, L. X. et al. Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression. Cell Death Dis. 9, 326. https:\/\/doi.org\/10.1038\/s41419-018-0347-x (2018).","journal-title":"Cell Death Dis."},{"key":"55155_CR31","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.leukres.2014.01.013","volume":"38","author":"LH Sakamoto","year":"2014","unstructured":"Sakamoto, L. H., Andrade, R. V., Felipe, M. S., Motoyama, A. B. & Pittella Silva, F. SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor. Leuk. Res. 38, 496\u2013502. https:\/\/doi.org\/10.1016\/j.leukres.2014.01.013 (2014).","journal-title":"Leuk. Res."},{"key":"55155_CR32","first-page":"997","volume":"10","author":"F Meng","year":"2020","unstructured":"Meng, F. et al. SMYD2 suppresses APC2 expression to activate the Wnt\/\u03b2-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer. Am. J. Cancer Res. 10, 997\u20131011 (2020).","journal-title":"Am. J. Cancer Res."},{"key":"55155_CR33","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.1349-7006.2012.02214.x","volume":"103","author":"A Shimizu","year":"2012","unstructured":"Shimizu, A. et al. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci. 103, 739\u2013746. https:\/\/doi.org\/10.1111\/j.1349-7006.2012.02214.x (2012).","journal-title":"Cancer Sci."},{"key":"55155_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1196\/annals.1294.016","volume":"1014","author":"RB Hazan","year":"2004","unstructured":"Hazan, R. B., Qiao, R., Keren, R., Badano, I. & Suyama, K. Cadherin switch in tumor progression. Ann. N. Y. Acad. Sci. 1014, 155\u2013163. https:\/\/doi.org\/10.1196\/annals.1294.016 (2004).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"55155_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101118","author":"CY Loh","year":"2019","unstructured":"Loh, C. Y. et al. The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. Cells https:\/\/doi.org\/10.3390\/cells8101118 (2019).","journal-title":"Cells"},{"key":"55155_CR36","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/bjc.2011.452","volume":"105","author":"K Araki","year":"2011","unstructured":"Araki, K. et al. E\/N-cadherin switch mediates cancer progression via TGF-\u03b2-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br. J. Cancer 105, 1885\u20131893. https:\/\/doi.org\/10.1038\/bjc.2011.452 (2011).","journal-title":"Br. J. Cancer"},{"key":"55155_CR37","first-page":"3406","volume":"9","author":"Y Ding","year":"2003","unstructured":"Ding, Y. et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin. Cancer Res. 9, 3406\u20133412 (2003).","journal-title":"Clin. Cancer Res."},{"key":"55155_CR38","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3892\/ijo_00000217","volume":"34","author":"K Ishida","year":"2009","unstructured":"Ishida, K. et al. High CCR7 mRNA expression of cancer cells is associated with lymph node involvement in patients with esophageal squamous cell carcinoma. Int. J. Oncol. 34, 915\u2013922. https:\/\/doi.org\/10.3892\/ijo_00000217 (2009).","journal-title":"Int. J. Oncol."},{"key":"55155_CR39","first-page":"2937","volume":"62","author":"K Mashino","year":"2002","unstructured":"Mashino, K. et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 62, 2937\u20132941 (2002).","journal-title":"Cancer Res."},{"key":"55155_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/35065016","volume":"410","author":"A M\u00fcller","year":"2001","unstructured":"M\u00fcller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50\u201356. https:\/\/doi.org\/10.1038\/35065016 (2001).","journal-title":"Nature"},{"key":"55155_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-015-0268-9","volume":"34","author":"M Shi","year":"2015","unstructured":"Shi, M., Chen, D., Yang, D. & Liu, X. Y. CCL21-CCR7 promotes the lymph node metastasis of esophageal squamous cell carcinoma by up-regulating MUC1. J. Exp. Clin. Cancer Res. 34, 149. https:\/\/doi.org\/10.1186\/s13046-015-0268-9 (2015).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"55155_CR42","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1074\/jbc.M111.294876","volume":"287","author":"YK Mburu","year":"2012","unstructured":"Mburu, Y. K. et al. Chemokine receptor 7 (CCR7) gene expression is regulated by NF-\u03baB and activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN). J. Biol. Chem. 287, 3581\u20133590. https:\/\/doi.org\/10.1074\/jbc.M111.294876 (2012).","journal-title":"J. Biol. Chem."},{"key":"55155_CR43","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1084\/jem.20020062","volume":"196","author":"M Hinz","year":"2002","unstructured":"Hinz, M. et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin\u2019s disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J. Exp. Med. 196, 605\u2013617. https:\/\/doi.org\/10.1084\/jem.20020062 (2002).","journal-title":"J. Exp. Med."},{"key":"55155_CR44","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1182\/blood.v99.4.1109","volume":"99","author":"UE H\u00f6pken","year":"2002","unstructured":"H\u00f6pken, U. E. et al. Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood 99, 1109\u20131116. https:\/\/doi.org\/10.1182\/blood.v99.4.1109 (2002).","journal-title":"Blood"},{"key":"55155_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01576-4","volume":"8","author":"H Ji","year":"2023","unstructured":"Ji, H. et al. Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions. Signal Transduct. Target. Ther. 8, 367. https:\/\/doi.org\/10.1038\/s41392-023-01576-4 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"55155_CR46","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1172\/JCI71606","volume":"124","author":"S Karaman","year":"2014","unstructured":"Karaman, S. & Detmar, M. Mechanisms of lymphatic metastasis. J. Clin. Invest. 124, 922\u2013928. https:\/\/doi.org\/10.1172\/JCI71606 (2014).","journal-title":"J. Clin. Invest."},{"key":"55155_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cells11040656","author":"CA Bill","year":"2022","unstructured":"Bill, C. A., Allen, C. M. & Vines, C. M. C-C Chemokine Receptor 7 in cancer. Cells https:\/\/doi.org\/10.3390\/cells11040656 (2022).","journal-title":"Cells"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55155-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55155-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55155-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:37:09Z","timestamp":1786405029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55155-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55155"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55155-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Wakayama Medical University Ethics Committee (approval number: 2521). Informed consent was obtained in the form of opt-out on the website (\n                      \n                      ). Those who declined were excluded.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24827"}}